Recommendation from Automobile & Ancillaries and Healthcare Sector
Ratin Biswass / 10 Jul 2025/ Categories: DSIJ_Magazine_Web, DSIJMagazine_App, Hot Chips, Hot Chips, Recommendations
The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations.
The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations.[EasyDNNnews:PaidContentStart]
Apollo Tyres Ltd
CMP - ₹471.70
BSE CODE 500877
Volume 1,17,632
Face Value ₹1
Target ₹510 - ₹520
Stoploss ₹440 (CLS)
Apollo Tyres Ltd is a prominent global tyre manufacturer and the leading tyre brand in India. It operates under two internationally recognized brands – Apollo and Vredestein – with a strong presence in over 100 countries, supported by a vast distribution network comprising branded, exclusive, and multi-product outlets. The company offers a comprehensive product portfolio that spans passenger cars, SUVs, MUVs, light trucks, truck-buses, two-wheelers, agricultural, industrial, specialty, bicycle, and off-theroad tyres. Recently, Apollo Tyres launched its latest Ultra-High Performance (UHP) tyre – the ‘Apollo Aspire 5’. Developed and manufactured in India, this new offering targets both domestic and international markets. On the financial front, while revenue growth remained modest, the company faced challenges in terms of profitability. However, investor sentiment improved after the company set July 11, 2025, as the record date for dividend payment. With the stock trading around 20 per cent below its 52-week high, there appears to be considerable upside potential, and we recommend BUY.
Krishna Institute of Medical Sciences Ltd
CMP - ₹701.10
BSE CODE 543308
Volume 52,247
Face Value ₹2
Target ₹755 - ₹770
Stoploss ₹650 (CLS)
It is among India’s largest corporate healthcare groups, with a strong presence across Telangana, Andhra Pradesh, Maharashtra, Karnataka, and Kerala. KIMS offers a wide spectrum of medical services across 25 specialties. For FY25, the company posted a strong financial performance, with revenue climbing by around 22 per cent to ₹3,035 crore compared to FY24. Net profit registered a healthy growth of more than 23 per cent, surging to ₹414.80 crore from ₹336.20 crore in the previous fiscal, reflecting improved operational efficiency and sustained business momentum. Given the essential nature of its business, strong sectoral tailwinds, and the company’s consistent financial performance, it is well-positioned for robust growth ahead. The stock has regained momentum after a brief consolidation phase and is currently trading near its 52-week high, having delivered impressive returns of around 70 per cent over the past year. Considering the continued upside potential, we recommend BUY.
[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]
To read the entire article, you must be a DSIJ magazine subscriber.
[EasyDNNnews:UnPaidContentEnd]